Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Biclodil. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | TYK2 | P29597 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | F2 | P00734 | 1/20 | 0.41 |
| ▸ | F10 | P00742 | 1/20 | 0.41 |
| ▸ | PLAU | P00749 | 1/20 | 0.41 |
| ▸ | PLAT | P00750 | 1/20 | 0.41 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.41 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.41 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.41 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Biclodil SCHEMBL1815631 | 0.98 | CYP1A2 (0.49) | CYP1A2TYK2MEN1LMNAKMT2A | |
| SCHEMBL11093872 | 0.87 | CYP1A2 (0.43) | CYP1A2TYK2MEN1LMNAKMT2A | |
| SCHEMBL4099006 | 0.87 | GAA (0.51) | CYP1A2PDK1PDK2PDK3PDK4 | |
| SCHEMBL11093150 | 0.87 | CYP1A2 (0.43) | CYP1A2TYK2MEN1LMNAKMT2A | |
| SCHEMBL11090448 | 0.87 | GAA (0.43) | CYP1A2TYK2MEN1KMT2AF2 | |
| Hydrochloric Acid SCHEMBL16701798 | 0.86 | TYK2 (0.38) | CYP1A2TYK2MEN1LMNAKMT2A | |
| SCHEMBL11089784 | 0.85 | L3MBTL1 (0.47) | CYP1A2TYK2LMNAPDK1PDK2 | |
| SCHEMBL11437504 | 0.84 | TYK2 (0.44) | CYP1A2TYK2MEN1LMNAKMT2A | |
| SCHEMBL4206477 | 0.84 | TYK2 (0.39) | CYP1A2TYK2MEN1LMNAKMT2A | |
| SCHEMBL11579842 | 0.84 | GAA (0.40) | CYP1A2TYK2MEN1LMNAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 300 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8268352-B2 | Modified release composition for highly soluble drugs | TORRENT PHARMACEUTICALS LIMITED (IN) | 2012-09-18 | — | — | US | claimed |
| US-8263125-B2 | Dosage form for high dose-high solubility active ingredients that provides for immediate release and modified release of the active ingredients | TORRENT PHARMACEUTICALS LIMITED (IN) | 2012-09-11 | — | — | US | claimed |
| US-20060024365-A1 | Novel dosage form | VAYA NAVIN | 2006-02-02 | — | — | US | claimed |
| US-20060018933-A1 | Novel drug delivery system | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-01-26 | — | — | US | claimed |
| US-20060018934-A1 | Novel drug delivery system | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-01-26 | — | — | US | claimed |
| US-20020115655-A1 | Such as S-(4-methoxybenzyl)-N-(2-(N',N'-dimethylamino)ethyl) thiosalicylamide; for treatment of cardiovascular disorders | MASSACHUSETTS COLLEGE OF PHARMACY | 2002-08-22 | — | — | US | claimed |
| US-12605333-B2 | Modified release drug powder composition comprising gastro-retentive raft forming systems having trigger pulse drug release | TRIS PHARMA, INC. (US) | 2026-04-21 | — | — | US | disclosed |
| US-20260096986-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING A FLOATING INTERPENETRATING POLYMER NETWORK FORMING SYSTEM | TRIS PHARMA INC (US) | 2026-04-09 | — | — | US | disclosed |
| EP-4706683-A2 | CHEWABLE FORMULATIONS | Elanco Tiergesundheit AG (CH) | 2026-03-11 | — | — | EP | disclosed |
| US-20260034059-A1 | ORAL FILM COMPOSITIONS AND DOSAGE FORMS HAVING PRECISE ACTIVE DISSOLUTION PROFILES | AQUESTIVE THERAPEUTICS, INC. (US) | 2026-02-05 | — | — | US | disclosed |
| US-12514818-B2 | Pharmaceutical compositions comprising a floating interpenetrating polymer network forming system | TRIS PHARMA, INC. (US) | 2026-01-06 | — | — | US | disclosed |
| US-12465564-B2 | Oral and nasal compositions and methods of treatment | AQUESTIVE THERAPEUTICS, INC. (US) | 2025-11-11 | — | — | US | disclosed |
| US-20250339367-A1 | ORAL FILM COMPOSITIONS AND DOSAGE FORMS HAVING PRECISE ACTIVE DISSOLUTION PROFILES | AQUESTIVE THERAPEUTICS, INC. (US) | 2025-11-06 | — | — | US | disclosed |
| WO-2000050020-A2 | USE OF SULFAMATE DERIVATIVES FOR TREATING IMPULSE CONTROL DISORDERS | UNIVERSITY OF CINCINNATI (US) | 2000-08-31 | — | — | WO | disclosed |
| WO-1999030690-A1 | ORAL DELIVERY FORMULATION | AXIA THERAPEUTICS, INC. (US) | 1999-06-24 | — | — | WO | disclosed |
| EP-0909183-A2 | DHA-PHARMACEUTICAL AGENT CONJUGATES | Neuromedica, Inc. (US) | 1999-04-21 | — | — | EP | disclosed |
| US-5795909-A | ANTICARCINOGENIC AND ANTITUMOR AGENTS; BREAST, COLON, OVARIANCANCERS | NEUROMEDICA, INC. (US) | 1998-08-18 | — | — | US | disclosed |
| WO-1997044063-A2 | DHA-PHARMACEUTICAL AGENT CONJUGATES | NEUROMEDICA, INC. (US) | 1997-11-27 | — | — | WO | disclosed |
| US-4446152-A | SUBSTITUTED PHENYLAMIDINOUREA | WILLIAM H. RORER, INC. (US) | 1984-05-01 | — | — | US | disclosed |
| US-4088785-A | HYPOTENSIVE AGENTS | WILLIAM H. RORER, INC. (US) | 1978-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260096986-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING A FLOATING INTERPENETRATING POLYMER NETWORK FORMING SYSTEM | SI, FABP2, FABP6 | CYP1A2 695/4885TYK2 2818/4885MEN1 3578/4885 |
| US-12605333-B2 | Modified release drug powder composition comprising gastro-retentive raft forming systems having trigger pulse drug release | SI, GRPR, FABP2 | CYP1A2 1688/4885TYK2 715/4885MEN1 4654/4885 |
| US-20260034059-A1 | ORAL FILM COMPOSITIONS AND DOSAGE FORMS HAVING PRECISE ACTIVE DISSOLUTION PROFILES | SORD, SLC6A13, CACNA1A | CYP1A2 333/4885TYK2 2427/4885MEN1 2827/4885 |
| US-20020115655-A1 | Such as S-(4-methoxybenzyl)-N-(2-(N',N'-dimethylamino)ethyl) thiosalicylamide; for treatment of cardiovascular disorders | CACNA1G, CACNA1F, CACNA1H | CYP1A2 1771/4885TYK2 4681/4885MEN1 1866/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.